Your session is about to expire
Sinemet vs Stalevo
Introduction
For patients with Parkinson's disease or Parkinson-like symptoms, certain drugs that alter the levels of specific neurotransmitters in the brain can help manage tremors, stiffness and other mobility challenges. Sinemet and Stalevo are two such medications often prescribed for these conditions. Both impact dopamine levels in the brain necessary for coordinated movement but do so quite differently. Sinemet is a combination medication consisting of carbidopa and levodopa; it works by increasing the level of dopamine in the brain improving nerve signal transmission and motor function. On the other hand, Stalevo is a three-drug compound comprised of levodopa, carbidopa, and entacapone which not only increases dopamine synthesis but also prolongs its effects by inhibiting an enzyme called COMT (Catechol-O-methyltransferase) responsible for breaking down naturally occurring dopamine.
Sinemet vs Stalevo Side By Side
| Attribute | Sinemet | Stalevo |
|---|---|---|
| Brand Name | Sinemet | Stalevo |
| Contraindications | Should not be taken with or shortly after MAO inhibitors. Caution when switching brands due to bioequivalence differences. | Should not be taken with or shortly after MAO inhibitors. Caution when switching brands due to bioequivalence differences. |
| Cost | Brand name: Around $200 for 100 tablets (25-100 mg). Generic: $0.20 to $1.00 per day. | Brand name: Around $450 for 30 tablets (50 mg). Generic: $0.60 to $2.40 per day. |
| Generic Name | Carbidopa-Levodopa | Levodopa, Carbidopa, and Entacapone |
| Most Serious Side Effect | Neuroleptic malignant syndrome, sudden unusual changes in mood or behavior, vision problems. | Severe diarrhea leading to weight loss and malnutrition, uncontrolled muscle movements. |
| Severe Drug Interactions | MAO inhibitors | MAO inhibitors |
| Typical Dose | 25/100 mg up to three times per day, up to a maximum of 2000 mg levodopa per day. | 100/25/200 mg per day, up to a maximum of 800/200/200 mg/day. |
What is Sinemet?
Carbidopa-levodopa (the generic name for Sinemet) was a significant improvement over the first generation of Parkinson's disease medications, and it continues to be a widely used treatment option. First approved by the FDA in 1975, Sinemet increases levels of dopamine in the brain by providing its precursor, levodopa, which can cross the blood-brain barrier. It is co-administered with carbidopa which prevents levodopa from being converted into dopamine outside of the brain, thereby increasing its efficacy and reducing peripheral side effects.
Stalevo is another medication also used for treating symptoms related to Parkinson’s disease but it includes an additional component - entacapone. This helps prolong the effect of levodopa by inhibiting COMT enzyme (Catechol-O-methyltransferase), further slowing down levodopa's breakdown before it reaches the brain.
Both drugs aim at managing Parkinson’s symptoms; however they differ in their components and their influence on different biochemical pathways involved in dopamine synthesis and metabolism.
What conditions is Sinemet approved to treat?
Sinemet and Stalevo are both approved for the treatment of Parkinson's disease:
-
Sinemet is used to treat symptoms such as shakiness, stiffness, and difficulty moving. It may also be used to treat Parkinson-like symptoms caused by certain conditions (e.g., encephalitis, carbon monoxide poisoning).
-
Stalevo contains an extra component called entacapone along with levodopa and carbidopa (the two drugs in Sinemet). This combination helps prolong the effects of levodopa and can reduce "off" time - periods when medication wears off and Parkinson's symptoms return.
How does Sinemet help with these illnesses?
Sinemet aids in the management of Parkinson's disease by increasing the amount of dopamine available in the brain. It works by incorporating levodopa, a substance that can cross into the brain and be converted into dopamine, thereby supplementing deficient levels of this neurotransmitter. Dopamine is a chemical messenger involved in coordinating smooth and controlled muscle movements. In people with Parkinson's disease, cells that produce dopamine start to die off leading to motor symptoms such as tremors, stiffness, and bradykinesia (slowness of movement). Sinemet helps these patients by boosting their dopamine levels which can help control these motor symptoms.
On the other hand, Stalevo not only contains levodopa but also carbidopa and entacapone. Carbidopa ensures more levodopa gets to your brain before being broken down elsewhere in your body while entacapone prolongs the effect of levodopa by inhibiting an enzyme called COMT which breaks it down prematurely. Therefore, Stalevo aims at enhancing and extending relief from motor symptoms associated with Parkinson’s Disease.
What is Stalevo?
Stalevo is a combination medication used for the treatment of Parkinson's disease, containing three active ingredients: levodopa, carbidopa and entacapone. Like Sinemet (which contains only levodopa and carbidopa), it works by increasing the levels of dopamine in the brain, thus reducing symptoms such as tremors, stiffness and slowness of movement associated with Parkinson's disease. However, Stalevo also includes entacapone, which inhibits an enzyme involved in breaking down levodopa in the body. This allows more levodopa to reach the brain where it can be converted into dopamine. Because Stalevo has this additional component compared to Sinemet, its side-effect profile may differ slightly; some patients might experience more gastrointestinal side effects or urine discoloration due to entacapone. However, for many people living with Parkinson’s disease who are not adequately controlled on levodopa/carbidopa alone (such as those taking Sinemet), adding a COMT inhibitor like entacapone can provide better symptom control throughout the day.
What conditions is Stalevo approved to treat?
Stalevo has been approved by the FDA for use in managing symptoms of Parkinson's disease. It is specifically designed to address the following conditions:
- Fluctuating motor functions and dyskinesias, common complications in advanced stages of Parkinson’s disease
- "Off" periods, where patients experience a re-emergence or worsening of their symptoms due to a decrease in medication effectiveness over time.
How does Stalevo help with these illnesses?
Stalevo is a medication that addresses the issue of dopamine deficiency, which is heavily implicated in Parkinson's disease. It contains levodopa, carbidopa and entacapone – three active ingredients that work together to increase the levels of dopamine in the brain thereby alleviating some of the symptoms associated with Parkinson’s disease. Stalevo works by enhancing both the extent and duration of levodopa availability in order to provide more constant stimulation to nerve cells. Its action on COMT enzymes reduces their activity and slows down metabolism of levodopa, thus prolonging its effect.
Unlike Sinemet (which only contains carbidopa/levodopa), Stalevo includes entacapone - an enzyme blocker that prevents rapid breakdown of levodopa before it reaches brain cells. Therefore, it may be used when patients have motor fluctuations or "wearing off" episodes with Sinemet alone.
How effective are both Sinemet and Stalevo?
Both carbidopa-levodopa (Sinemet) and levodopa-carbidopa-entacapone (Stalevo) have proven efficacy in treating symptoms of Parkinson’s disease, with their initial FDA approvals being 23 years apart. Both medications work by supplementing or replacing dopamine, a neurotransmitter that is progressively lost in the brains of individuals with Parkinson's. The direct comparison between Sinemet and Stalevo was made in several clinical trials; both drugs were found to be similarly effective at managing motor fluctuations associated with Parkinson’s disease.
A 2001 review on Sinemet affirmed its effectiveness from the first week of treatment, demonstrated an acceptable side effect profile relative to other antiparkinsonian therapies, and asserted it as well-tolerated across various populations. This study reported that Sinemet has become one of the most frequently prescribed drugs for symptomatic management in Parkinson's disease worldwide.
In contrast, a 2010 review indicated that while Stalevo also shows high efficacy against parkinsonian symptoms similar to Sinemet alone, it particularly shines at reducing "off" time - periods where medication effects wane leading to return of symptoms - due to its third component entacapone which prolongs the effect of levodopa. Despite this added benefit, Stalevo is usually considered after starting patients on traditional carbidopa/levodopa therapy like Sinemet primarily due to cost considerations or if there are concerns about additional side effects from entacapone like diarrhea or increased dyskinesia.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Sinemet typically prescribed?
Oral dosages of Sinemet range from 25/100 mg (carbidopa/levodopa) up to three times per day, but studies have indicated that a starting dose of one tablet of 25/100 mg three times per day is sufficient for treating symptoms in most people with Parkinson's disease. Dosage can be increased by one tablet every day or every other day, as necessary, until a dosage of eight tablets (max 2000 mg levodopa) per day is reached. In comparison, the standard initial dose for Stalevo is one tablet of Stalevo 50 (12.5 carbidopa /50 levodopa /200mg entacapone) three times daily and should not exceed more than eight tablets in any given day due to the limit on total daily intake for entacapone which is 1600mg/day. The dose may be adjusted according to the therapeutic need and tolerability.
At what dose is Stalevo typically prescribed?
Stalevo treatment is typically initiated at a dosage of 100/25/200 mg (levodopa, carbidopa, entacapone) per day. The dose can then be increased to a maximum of 800/200/200 mg/day, divided into multiple doses that are spaced apart throughout the day as directed by your doctor. An increase in dosage may be considered if there's no response to initial treatment after a few weeks. However, it's important to note that higher daily doses and more frequent administration may lead to an increased risk of certain side effects such as dyskinesia or abnormal involuntary movements. Always consult with your healthcare provider before making any changes to medication regimens.
What are the most common side effects for Sinemet?
Common side effects of Sinemet can include:
- Involuntary movements or tremors
- Nausea and vomiting
- Loss of appetite
- Dizziness, especially upon standing up quickly (orthostatic hypotension)
- Abnormal dreams and insomnia
- Dry mouth
- Anxiety or nervousness
- Lowered blood pressure which may cause fainting.
On the other hand, Stalevo has similar side effects but also includes:
- Diarrhea or constipation
- Muscle cramps, pain, stiffness or spasms
- Sweating excessively.
Always consult with your doctor if you experience any of these symptoms while taking either medication.
Are there any potential serious side effects for Sinemet?
When comparing Sinemet to Stalevo, it's important to be aware of the potential side effects. With both drugs, there can be serious adverse reactions such as:
- Thoughts about suicide or self-harm
- Signs of an allergic reaction including hives; difficulty breathing; swelling in your face, lips, tongue, or throat
- Sudden unusual changes in mood or behavior (including confusion, depression)
- Chest pain and irregular heartbeat
- High fever and stiff muscles which may indicate a severe nervous system reaction known as neuroleptic malignant syndrome
- Vision problems like blurred vision or dilated pupils;
In addition with Stalevo specifically one might experience:
- Diarrhea leading to excessive weight loss and malnutrition due its entacapone component.
Signs indicating low dopamine levels in the body include muscle stiffness, twitching and spasms. If you observe any symptoms like these while taking either medication stop usage immediately and consult your healthcare provider.
What are the most common side effects for Stalevo?
Stalevo, a medication used to treat Parkinson's symptoms, can lead to several side effects:
- Dry mouth or throat
- Nausea, vomiting, stomach pain and constipation
- Loss of appetite
- Sleep problems (insomnia), drowsiness during the day
- Blurred vision
- Unusual sweating and feeling anxious
- Increased urination
- Headache or dizziness -Stiff muscles or muscle spasms, -Involuntary movement control problems. Remember that each patient experiences side effects differently. It's crucial to keep open communication with your healthcare provider regarding any unusual reactions while on Stalevo.
Are there any potential serious side effects for Stalevo?
In some cases, Stalevo may cause serious side effects. Be vigilant for the following symptoms:
- Signs of an allergic reaction or severe skin issues: this could look like hives, itching, fever, swollen glands, difficulty breathing, swelling in your face or throat. You might also experience a sore throat, burning eyes, skin pain or develop a red/purple skin rash that blisters and peels.
- Uncontrolled muscle movements in your face (chewing, lip smacking etc.), tongue or neck
- Hallucinations and confusion
- Agitation and uncharacteristically aggressive behavior
- Light-headedness as if you are about to faint
- Diarrhea that is watery or bloody Impulsive behavior - unusual urges such as cravings for gambling
If you encounter any of these symptoms after taking Stalevo please reach out to your healthcare provider immediately.
Contraindications for Sinemet and Stalevo?
Both Sinemet and Stalevo, like most Parkinson's disease medications, may worsen symptoms of the disease in some individuals. If you notice your symptoms worsening or an increase in unusual behavior or thoughts, seek immediate medical attention.
Neither Sinemet nor Stalevo should be taken if you are taking, or have recently been on monoamine oxidase (MAO) inhibitors. Always inform your physician about any medications you're currently taking; MAOIs will require a period of approximately 2 weeks to clear from your system to prevent dangerous interactions with both Sinemet and Stalevo.
Furthermore, caution should be exercised when switching between different brands of these drugs as they might not have the same bioequivalence which could lead to changes in efficacy and tolerability.
How much do Sinemet and Stalevo cost?
For the brand name versions of these drugs:
- The price for 100 tablets of Sinemet (25-100 mg) averages around $200, which works out to approximately $4-$8/day, depending on your dose.
- The price for 30 tablets of Stalevo (50 mg) averages about $450, working out to roughly $15/day.
Thus, if you are in the higher dosage range for Sinemet (i.e., 300 mg/day or higher), then brand-name Stalevo is more expensive on a per-day treatment basis. However, cost should not be a primary consideration in determining which of these drugs is right for you.
As far as generic versions go:
-
Carbidopa/Levodopa (generic version of Sinemet) costs significantly less with prices ranging from about $0.20 to $1.00 per day based on dosages between 150mg and 600mg daily.
-
Entacapone with Levodopa and Carbidopa (generic version of Stalevo) also has lower costs than its branded counterpart with prices averaging between approximately $0.60 to nearly $2.40 per day based on common dosages used in Parkinson's disease treatment.
Popularity of Sinemet and Stalevo
Carbidopa/Levodopa, in generic form as well as brand names such as Sinemet, was estimated to have been prescribed to about 1.4 million people in the US in 2020. This medication accounted for nearly 80% of prescriptions given for Parkinson's disease treatment in the US and is considered one of the most effective treatments available. Carbidopa/Levodopa has maintained a consistent prevalence since its introduction.
On comparison, Entacapone with Levodopa and Carbidopa, commercially known as Stalevo, was prescribed to approximately 100 thousand people in the USA in 2020. In terms of overall Parkinson’s disease medications prescriptions within the country, Stalevo covers about a modest share but it has seen an increase over time due to its unique formulation that combines three active ingredients which can provide additional benefit for some patients.
Conclusion
Both Sinemet (carbidopa-levodopa) and Stalevo (carbidopa-levodopa and entacapone) are commonly prescribed treatments for Parkinson's disease, with a solid record of effectiveness in managing motor symptoms. These drugs work by replacing dopamine or enhancing its effect, which is reduced in patients suffering from this condition.
In some circumstances, the two medications may be used together; however it is crucial that this decision is made under the careful guidance of a healthcare provider due to potential interactions between these medicines. The key distinguishing feature between them lies in their composition: while both contain carbidopa and levodopa, Stalevo also includes an additional component called entacapone, which can further enhance the duration of action of levodapa.
Sinemet is typically considered as the first-line treatment option for most patients newly diagnosed with Parkinson's disease. On the other hand, Stalevo tends to be introduced if patients on Sinemet start experiencing 'wearing off' effects before their next dose or have fluctuating response issues.
Both drugs come in generic versions providing significant cost savings particularly for those who need to pay out-of-pocket expenses. It should be noted that both Sinemet and Stalevo might take time before showing noticeable improvements -- hence they require patience during initial days of therapy.
The side-effects associated with each drug are quite similar since they share common components; but individuals on Stalevo might experience additional side effects related to entacapone like diarrhea or increased urine discoloration due to its additional component. As always individuals must watch closely any changes especially worsening motor symptoms or unusual mood changes when starting these therapies and consult medical help promptly if any alarming signs appear.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Koller, W., Guarnieri, M., Hubble, J., Rabinowicz, A. L., & Silver, D. (2004, October 22). An open-label evaluation of the tolerability and safety of Stalevo� (carbidopa, levodopa and entacapone) in Parkinson?s disease patients experiencing wearing-off. Journal of Neural Transmission. Springer Science and Business Media LLC.http://doi.org/10.1007/s00702-004-0184-1
- Hauser, R. A. (2004, January 13). Levodopa/carbidopa/entacapone (Stalevo). Neurology. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1212/wnl.62.1_suppl_1.s64
- Hauser, R. A., Panisset, M., Abbruzzese, G., Mancione, L., Dronamraju, N., Kakarieka, A., & on behalf of the FIRST‐STEP Study Group. (2009, March 15). Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Movement Disorders. Wiley.http://doi.org/10.1002/mds.22343
- Brooks, D. J., Agid, Y., Eggert, K., Widner, H., Østergaard, K., & Holopainen, A. (2005). Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo<sup>®</sup> (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess<sup>®</sup>/Comtan<sup>®</sup> (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment. European Neurology. S. Karger AG.http://doi.org/10.1159/000086479
- &NA;. (2003). Entacapone/Levodopa/Carbidopa Combination Tablet. Drugs in R & D. Springer Science and Business Media LLC.http://doi.org/10.2165/00126839-200304050-00006
- Koller, W., Guarnieri, M., Hubble, J., Rabinowicz, A. L., & Silver, D. (2004, October 22). An open-label evaluation of the tolerability and safety of Stalevo� (carbidopa, levodopa and entacapone) in Parkinson?s disease patients experiencing wearing-off. Journal of Neural Transmission. Springer Science and Business Media LLC.http://doi.org/10.1007/s00702-004-0184-1
- Brooks, D. J., Agid, Y., Eggert, K., Widner, H., Østergaard, K., & Holopainen, A. (2005). Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo<sup>®</sup> (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess<sup>®</sup>/Comtan<sup>®</sup> (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment. European Neurology. S. Karger AG.http://doi.org/10.1159/000086479
- Silver, D. E. (2004, July). Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo®). Expert Review of Neurotherapeutics. Informa UK Limited.http://doi.org/10.1586/14737175.4.4.589